Australia needs reform of financing model, but medtech is good "value for money"
This article was originally published in Clinica
The Productivity Commission's final report on the Impacts of Advances in Medical Technology in Australia has found that the benefits of medical technology advances have "arguably provided value for money". The way forward, to ensure the cost-effectiveness of future advances, lies in a reform of assessment methods and financing models.
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.